In patients with non-progressive CLL, management is similar to primary immune thrombocytopenic purpura with corticosteroids, Intravenous immunoglobulin, rituximab, thrombopoietin receptor agonists, and splenectomy in refractory cases. Here, MPL is linked to autoimmune thrombocytopenic purpura.